WINTON GROUP Ltd Sells 14,985 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

   2019-08-03 01:08

WINTON GROUP Ltd lowered its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 49.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,167 shares of the medical research company’s stock after selling 14,985 shares during the period. WINTON GROUP Ltd’s holdings in NeoGenomics were worth $333,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the company. Legal & General Group Plc raised its stake in shares of NeoGenomics by 13.3% during the 4th quarter. Legal & General Group Plc now owns 11,964 shares of the medical research company’s stock worth $151,000 after purchasing an additional 1,405 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in NeoGenomics by 0.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 401,857 shares of the medical research company’s stock valued at $8,222,000 after acquiring an additional 2,834 shares during the period. Great West Life Assurance Co. Can raised its stake in NeoGenomics by 53.9% in the 4th quarter. Great West Life Assurance Co. Can now owns 9,851 shares of the medical research company’s stock valued at $120,000 after acquiring an additional 3,451 shares during the period. Norris Perne & French LLP MI raised its stake in NeoGenomics by 1.8% in the 1st quarter. Norris Perne & French LLP MI now owns 342,629 shares of the medical research company’s stock valued at $7,004,000 after acquiring an additional 6,051 shares during the period. Finally, CIBC Private Wealth Group LLC raised its stake in NeoGenomics by 8.0% in the 1st quarter. CIBC Private Wealth Group LLC now owns 85,877 shares of the medical research company’s stock valued at $1,757,000 after acquiring an additional 6,372 shares during the period. Institutional investors own 84.07% of the company’s stock.



A number of equities research analysts recently weighed in on NEO shares. Raymond James increased their price target on NeoGenomics from $23.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday. Leerink Swann set a $30.00 price target on NeoGenomics and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research cut NeoGenomics from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Needham & Company LLC set a $27.00 price target on NeoGenomics and gave the company a “buy” rating in a research note on Wednesday. Finally, BidaskClub upgraded NeoGenomics from a “hold” rating to a “buy” rating in a research note on Friday, July 19th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $23.78.

In other news, insider William Bonello sold 7,200 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $23.53, for a total transaction of $169,416.00. Following the sale, the insider now directly owns 13,935 shares of the company’s stock, valued at approximately $327,890.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Raymond R. Hipp sold 150,000 shares of the stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $22.41, for a total value of $3,361,500.00. Following the sale, the director now directly owns 256,059 shares in the company, valued at $5,738,282.19. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

NASDAQ NEO traded down $1.60 on Friday, reaching $24.25. The stock had a trading volume of 547,592 shares, compared to its average volume of 641,858. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.46 and a current ratio of 4.67. The stock’s fifty day moving average is $23.12. NeoGenomics, Inc. has a 1-year low of $11.05 and a 1-year high of $25.98. The stock has a market capitalization of $2.47 billion, a P/E ratio of 186.54 and a beta of 0.78.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, July 30th. The medical research company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. NeoGenomics had a return on equity of 4.08% and a net margin of 0.57%. The firm had revenue of $101.71 million for the quarter, compared to analyst estimates of $97.32 million. During the same period in the prior year, the firm posted $0.05 EPS. The company’s revenue for the quarter was up 50.1% on a year-over-year basis. Analysts forecast that NeoGenomics, Inc. will post 0.18 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Further Reading: Do stock splits help investors?

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.


Original Source